The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.
 
Daniel Shao-Weng Tan
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Novartis
Research Funding - Bayer; GlaxoSmithKline; Novartis
Travel, Accommodations, Expenses - Merck; Novartis
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech
 
Natasha B. Leighl
Research Funding - Novartis (Inst)
 
Gregory J. Riely
Honoraria - Celgene
Consulting or Advisory Role - ARIAD; Mersana; Novartis; Novartis; Roche
Research Funding - GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Novartis
 
Lecia V. Sequist
Consulting or Advisory Role - ARIAD; AstraZeneca; Clovis Oncology; Genentech; Merrimack; Novartis; Taiho Pharmaceutical
Research Funding - ArQule (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Enriqueta Felip
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Roche
 
Takashi Seto
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Fuji Pharma; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Mochida Pharmaceutical Co. Ltd.; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Roche; Sanofi; Showa Yakuhin Kako; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Verastem (Inst); Yakult Pharmaceutical (Inst)
 
Juergen Wolf
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Novartis; Pfizer; Roche
Research Funding - Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Novartis; Pfizer; Roche
 
Susan Elizabeth Moody
Employment - Novartis
Consulting or Advisory Role - N-of-One
 
Kenneth Adams
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Shu-Fang Hsu Schmitz
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Eugene Y. Tan
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
Dong-Wan Kim
No Relationships to Disclose